BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang CY, Pham PN, Thai TN, Brown JD. Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles. Pharmacoeconomics 2020;38:1333-43. [PMID: 32924092 DOI: 10.1007/s40273-020-00960-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Sussman M, Di Fusco M, Tao CY, Guo JD, Gillespie JA, Ferri M, Adair N, Cato MS, Shirkhorshidian I, Barnes GD. The IMPact of untReated nOn-Valvular atrial fibrillation on short-tErm clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model. J Med Econ 2021;24:1070-82. [PMID: 34415229 DOI: 10.1080/13696998.2021.1970954] [Reference Citation Analysis]
2 Wu Y, Zhang C, Gu ZC. Cost-Effectiveness Analysis of Direct Oral Anticoagulants Vs. Vitamin K Antagonists in the Elderly With Atrial Fibrillation: Insights From the Evidence in a Real-World Setting. Front Cardiovasc Med 2021;8:675200. [PMID: 34268343 DOI: 10.3389/fcvm.2021.675200] [Reference Citation Analysis]